P. Kleihues

Genetics · 2000–2016

A researcher in the Science corpus: 14 papers; trusts 4 researchers and is trusted by 9 researchers here, as inferred from the citation graph.

Subfields

• Genetics — 35 citations into it; #1,177 of 6,854 by trust here, #351 by citations
• Molecular Biology — 27 citations into it; #6,059 of 17,773 by trust here, #7,747 by citations
• Cancer Research — 19 citations into it; #545 of 1,780 by trust here, #758 by citations

Whom P. Kleihues trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. H. Ohgaki
2. A. E. Pegg
3. Takuya Watanabe
4. D. Louis
5. S. Nobusawa

Who trusts P. Kleihues overall

1. H. Ohgaki
2. D. Louis
3. McKinsey L. Goodenberger
4. S. Nobusawa
5. Takuya Watanabe
6. P. Delgado-López

Papers from P. Kleihues's perspective

Ordered by how strongly the researchers P. Kleihues trusts endorse each paper. Same corpus, a different order for every researcher.

1. An Integrated Genomic Analysis of Human Glioblastoma Multiforme (Science)
2. Analysis of the IDH1 codon 132 mutation in brain tumors (Acta Neuropathologica)
3. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (Nature)
4. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (Cancer Cell)
5. IDH1 and IDH2 mutations in gliomas. (New England Journal of Medicine)
6. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. (Cancer Cell)
7. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α (Science)
8. Pathology and genetics of tumours of the nervous system.
9. Prediction of central nervous system embryonal tumour outcome based on gene expression (Nature)
10. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. (The Lancet)

Their papers

• Epidemiology and etiology of gliomas (2005) — 1,299 citations
• IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas (2009) — 712 citations
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. (2009) — 1,019 citations
• Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. (2005) — 1,375 citations
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary (2016) — 14,109 citations
• The Definition of Primary and Secondary Glioblastoma (2012) — 1,044 citations
• The 2007 WHO Classification of Tumours of the Central Nervous System (2007) — 12,930 citations
• The 2007 WHO classification of tumours of the central nervous system (2007) — 605 citations
• Genetic pathways to primary and secondary glioblastoma. (2007) — 1,541 citations
• Genetic Pathways to Glioblastoma (2004) — 779 citations
• World Cancer Report (2003) — 4,373 citations
• The WHO Classification of Tumors of the Nervous System (2002) — 1,935 citations
• Pathology and genetics of tumours of the nervous system. (2000) — 1,451 citations
• World Health Organization classification of tumors (2000) — 2,870 citations